AWA
CTXR icon

Arkadios Wealth Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Arkadios Wealth Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,600
Closed -$314 – 745
2023
Q4 		$314 Hold
16,600
– – ﹤0.01% 734
2023
Q3 		$284 Buy
+16,600
New +$395K ﹤0.01% 711

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Arkadios Wealth Advisors's CTXR Position: Q1 2026 in Review

Arkadios Wealth Advisors held its Citius Pharmaceuticals (CTXR) position steady in Q1 2026 at 20,000 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #1673.

Arkadios Wealth Advisors first reported a position in CTXR in Q3 2023 and has held it in 11 quarters since. The position peaked at $100K in Q3 2024. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Arkadios Wealth Advisors held 20,000 shares of Citius Pharmaceuticals worth $18K as of Q1 2026.
  • Arkadios Wealth Advisors left its Citius Pharmaceuticals share count unchanged in Q1 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of Arkadios Wealth Advisors's portfolio in Q1 2026, its #1673 holding.
  • Arkadios Wealth Advisors first reported a position in Citius Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Arkadios Wealth Advisors's Citius Pharmaceuticals position peaked at $100K in Q3 2024.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.